NCT07382726 2026-02-20
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Kura Oncology, Inc.
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Incyte Corporation
Mirati Therapeutics Inc.
M.D. Anderson Cancer Center